Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Dosing of VT-464 begins in phase I/II study

Jan. 9, 2012

University of Arizona scientists assess natural monoterpene in phase I trial

Jan. 9, 2012

Presurgical trial set to investigate MK-2206 in operable invasive cancer

Jan. 9, 2012

Alchemia treats first patient in pivotal phase III HA-irinotecan trial

Jan. 5, 2012

Phase II trial assesses proprietary Exelixis drug in metastatic breast cancer

Jan. 5, 2012

Dual ERK inhibitor shows promise as triple-negative breast cancer therapy

Jan. 5, 2012

Phase II results disclosed on PD-0332991

Jan. 5, 2012

Phase II data presented on PEGylated therapy in previously treated metastatic breast cancer

Jan. 5, 2012

Tragara multikinase inhibitor may be beneficial to treat triple-negative breast cancer

Jan. 5, 2012

Phase I/II CF-102 trials meet primary endpoints

Jan. 4, 2012

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...